+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Allergy Immunotherapy Market - Global Forecast 2026-2032- Product Image
Allergy Immunotherapy Market - Global Forecast 2026-2032- Product Image
Sale

Allergy Immunotherapy Market - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4905050
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Allergy Immunotherapy Market is projected to reach USD 2.24 Billion in 2026. It is expected to continue growing at a CAGR of 10.36%, reaching USD 4.07 Billion by 2032.

Allergy immunotherapy is the only disease-modifying treatment class designed to induce immune tolerance to clinically relevant allergens rather than only suppress symptoms. In practice, subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are used for allergic rhinitis, allergic conjunctivitis, selected allergic asthma, venom hypersensitivity, and specific inhalant allergens such as grass pollen, ragweed, birch, and house dust mite.

The allergy immunotherapy market is shaped by the persistent global burden of allergic rhinitis and asthma, guideline-backed use in appropriately selected patients, and rising demand for long-term control when antihistamines, intranasal corticosteroids, and allergen-avoidance strategies are insufficient. Regulatory agencies, including the U.S. FDA and European medicines authorities, continue to emphasize standardized allergen extracts, evidence-based labeling, pharmacovigilance, and patient safety, while professional societies such as EAACI, AAAAI, ACAAI, and ARIA reinforce the role of allergen immunotherapy in integrated allergy care.

Commercial momentum is strongest where accurate diagnosis, specialist referral, reimbursement, and adherence support converge. Stakeholders that combine clinically validated products, reliable allergen extract supply, digital adherence tools, and real-world evidence generation are best positioned in the allergy immunotherapy market.

Transformative Shifts in the Allergy Immunotherapy Landscape

The allergy immunotherapy landscape is moving from clinic-administered, extract-centered models toward more standardized, patient-centric, evidence-driven care. SLIT tablets have expanded the treatment conversation by offering convenient, at-home maintenance dosing after supervised initiation, while SCIT remains widely used because clinicians can tailor extract combinations to sensitization profiles under controlled protocols.

Several structural shifts are redefining competition. Climate-related pollen season lengthening, urban air pollution exposure, indoor allergen exposure, and higher awareness of allergic rhinitis and asthma comorbidity are increasing demand for durable interventions. At the same time, regulators and payers are scrutinizing clinical endpoints, product consistency, safety monitoring, and long-term value, pushing manufacturers toward stronger trial design and post-market evidence.

The market is also shifting toward precision allergy management. Component-resolved diagnostics, molecular allergy testing, and better patient phenotyping help differentiate clinically relevant sensitization from cross-reactivity, improving candidate selection and reducing avoidable treatment failure. This supports a more outcome-oriented allergy immunotherapy market with higher emphasis on adherence, persistence, and measurable quality-of-life gains.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across allergy immunotherapy research, commercialization, and patient management. In discovery and development, AI can support allergen sequence analysis, epitope mapping, formulation optimization, and safety signal review, accelerating the identification of candidates with improved efficacy and tolerability profiles.

In clinical operations, AI-enabled analytics can help improve trial recruitment by matching sensitization patterns, symptom history, geography, pollen exposure, and comorbid asthma status to protocol requirements. In care delivery, predictive models can flag patients at risk of non-adherence, missed injections, adverse reactions, or symptom escalation, enabling more timely clinician outreach and improved treatment persistence.

The most credible AI impact will come from transparent, validated tools integrated with electronic health records, pharmacy data, diagnostic results, wearable data where available, and environmental exposure datasets such as pollen and air-quality monitoring. Industry leaders should treat AI as an evidence amplifier rather than a substitute for controlled trials, physician judgment, and regulatory-grade pharmacovigilance.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

In Asia-Pacific, allergy immunotherapy development is supported by large populations, rising urbanization, increasing recognition of allergic rhinitis and asthma, and expanding access to specialist care in China, India, Japan, South Korea, and Australia. Market maturity varies widely because reimbursement, allergen extract standardization, diagnostic coverage, and allergy specialist density differ across countries; however, demand is rising as patients seek longer-term symptom control and clinicians adopt more structured allergy testing pathways.

North America remains a highly developed allergy immunotherapy region, led by the United States and Canada, where SCIT is deeply embedded in allergy practice and FDA-approved SLIT tablets provide standardized options for selected allergens. Latin America, including Brazil and Mexico, presents a growing but uneven opportunity as private care access, diagnostic capacity, physician training, and availability of standardized extracts influence uptake across urban and specialty-care settings.

Europe is a mature and clinically influential allergy immunotherapy market supported by strong guideline adoption, national reimbursement structures, pharmacovigilance systems, and well-established regulatory expectations for product quality and evidence. The Middle East, particularly GCC countries, is gaining attention as allergic disease is influenced by dust exposure, indoor allergens, climate conditions, and air quality, while Africa remains an emerging opportunity where access to allergy diagnostics, specialist infrastructure, affordability, and consistent product supply are primary constraints.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are increasingly relevant as urban growth, air pollution exposure, and middle-class healthcare spending raise demand for allergy diagnosis and treatment, although reimbursement, standardized product availability, and specialist access remain inconsistent across member countries. The GCC is positioned for premium allergy care expansion because of healthcare investment, private-sector capacity, medical tourism activity, and environmental exposure to dust, molds, and indoor allergens.

The European Union provides one of the most structured environments for allergy immunotherapy, with harmonized regulatory expectations, established pharmacovigilance, and strong clinical society influence across allergic rhinitis, allergic asthma, and venom allergy care. BRICS countries represent high-volume potential, especially China, India, Brazil, and South Africa, but require localized pricing, scalable diagnostics, cold-chain reliability where applicable, and evidence that fits diverse public and private healthcare systems.

G7 markets offer a strong combination of regulatory clarity, payer evaluation, clinical infrastructure, and innovation financing, making them central to product launches, real-world evidence programs, and long-term adherence models. NATO countries overlap substantially with North American and European developed markets, where resilient supply chains, medical preparedness, cross-border quality standards, and established pharmacovigilance support stable access to regulated allergen immunotherapy products.

Key Country Insights Across Major Allergy Immunotherapy Markets

The United States is the largest single commercial opportunity within allergy immunotherapy because of its established allergist network, extensive SCIT use, FDA-regulated SLIT tablets, and payer-driven emphasis on documented medical necessity and guideline-aligned care. Canada shows steady demand through specialist-led allergy care and public-private reimbursement pathways, while Mexico and Brazil offer expanding private-market potential as diagnostic access, urban specialty care, and physician training improve.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from mature allergy practice patterns, guideline awareness, and established pathways for allergic rhinitis, asthma comorbidity assessment, and venom hypersensitivity management. Germany and France are particularly important because of their long-standing clinical adoption of allergen immunotherapy and emphasis on standardized products. Russia has demand potential due to allergic disease burden but faces market-access, regulatory, and supply-chain complexity, while the broader European environment continues to prioritize standardized extracts and evidence-based use.

China and India represent major long-term opportunities due to large allergic disease populations, urban air quality challenges, increasing healthcare spending, and expanding specialty care, though affordability, diagnostic coverage, and physician training remain critical. Japan, South Korea, and Australia are more developed Asia-Pacific markets with stronger regulatory systems, higher diagnostic awareness, and clearer clinical adoption pathways, making them attractive for standardized SLIT and high-quality SCIT portfolios supported by adherence monitoring and post-market evidence.

Actionable Recommendations for Allergy Immunotherapy Leaders

Industry leaders should prioritize differentiated evidence. Products and services need clear clinical positioning by allergen, patient phenotype, safety profile, adherence pattern, and long-term outcome, supported by randomized trials, registry data, and real-world evidence.

Manufacturers should strengthen supply-chain resilience for standardized allergen extracts, invest in physician and patient education, and build digital adherence programs that reduce discontinuation across multi-year treatment courses. Partnerships with diagnostic providers can improve patient selection and help align immunotherapy initiation with clinically relevant sensitization rather than sensitization alone.

Commercial teams should localize market access strategy by reimbursement maturity. In developed markets, value messaging should focus on disease modification, reduced symptom burden, lower medication reliance, and quality-of-life improvement; in emerging markets, success depends on affordability, specialist training, scalable diagnostic pathways, and reliable availability of regulated products.

Research Methodology

This executive summary is based on a structured secondary-research methodology using publicly available and verifiable sources, including regulatory guidance, professional society guidelines, peer-reviewed clinical literature, product labels, epidemiology publications, and health-system documentation. Sources considered include agencies and organizations such as the FDA, EMA, WHO-linked allergy literature, EAACI, AAAAI, ACAAI, ARIA, and national health authorities.

The analysis emphasizes triangulation across clinical evidence, regulatory status, regional healthcare infrastructure, reimbursement context, diagnostic access, and market-access conditions. No unsupported market sizing, market share, or speculative forecasting is included; insights are framed around documented disease burden, approved treatment modalities, observed care pathways, regulatory standards, and validated industry drivers.

Qualitative assessment was applied to compare regions, country groups, and major national markets based on specialist availability, diagnostic capacity, product standardization, patient adherence requirements, payer acceptance, pharmacovigilance systems, and supply-chain reliability.

Conclusion: Outlook for Allergy Immunotherapy

The allergy immunotherapy market is entering a more disciplined phase in which clinical credibility, product standardization, adherence support, and real-world outcomes determine competitive strength. SCIT remains foundational in specialist allergy practice, while SLIT expands convenience and standardization for selected allergens.

Future advancement will depend on precise diagnosis, patient selection, sustained treatment persistence, and evidence that demonstrates durable benefits beyond symptomatic relief. Stakeholders that combine validated immunotherapy portfolios with AI-enabled analytics, regional market access expertise, reliable supply chains, and strong pharmacovigilance will be best positioned to lead the next stage of allergy care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Allergy Immunotherapy Market, by Allergy Type
7.1. Introduction
7.2. Allergic Asthma
7.3. Allergic Rhinitis
7.4. Atopic Dermatitis
7.5. Urticaria
8. Allergy Immunotherapy Market, by Allergen Type
8.1. Introduction
8.2. Animal Dander
8.2.1. Cat Allergens
8.2.2. Dog Allergens
8.3. Dust Mites
8.4. Food Allergens
8.4.1. Egg Allergens
8.4.2. Milk Allergens
8.4.3. Peanut Allergens
8.4.4. Tree Nut Allergens
8.5. Pollen
9. Allergy Immunotherapy Market, by Immunotherapy Delivery Form
9.1. Introduction
9.2. Dermal Patch
9.3. Drops
9.4. Injections
9.5. Tablets
10. Allergy Immunotherapy Market, by Technology Platform
10.1. Introduction
10.2. Adjuvants
10.3. Nanotechnology-Based Platforms
10.4. Recombinant Allergens
11. Allergy Immunotherapy Market, by Treatment Type
11.1. Introduction
11.2. Epicutaneous Immunotherapy
11.3. Oral Immunotherapy
11.4. Subcutaneous Immunotherapy
11.5. Sublingual Immunotherapy
12. Allergy Immunotherapy Market, by End User
12.1. Introduction
12.2. Homecare Settings
12.3. Hospitals
12.4. Research & Academic Laboratories
12.5. Specialty Clinics
13. Allergy Immunotherapy Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
14. Allergy Immunotherapy Market, by Region
14.1. Asia-Pacific
14.2. North America
14.3. Latin America
14.4. Europe
14.5. Middle East
14.6. Africa
15. Allergy Immunotherapy Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Allergy Immunotherapy Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Adamis Pharmaceuticals Corporation
18.2. Aimmune Therapeutics Inc.
18.3. ALK-Abelló A/S
18.4. Allergopharma GmbH & Co. KG
18.5. Allergy Therapeutics plc
18.6. Allovate LLC
18.7. Anergis SA
18.8. ASIT Biotech SA
18.9. Biomay AG
18.10. Camallergy Ltd.
18.11. Circassia Pharmaceuticals Inc.
18.12. DBV Technologies SA
18.13. Desentum Oy
18.14. HAL Allergy B.V.
18.15. HollisterStier Allergy Inc.
18.16. Inimmune Corporation
18.17. Inmunotek S.L.
18.18. Intrommune Therapeutics, Inc.
18.19. Jubilant HollisterStier LLC
18.20. LETI Pharma S.L.
18.21. Leti-allergoid
18.22. Merck KGaA
18.23. Mylan N.V.
18.24. Novartis AG
18.25. Prota Therapeutics Pty Ltd
18.26. Siolta Therapeutics, Inc.
18.27. Stallergenes Greer International AG
18.28. Thermo Fisher Scientific Inc.
18.29. Torii Pharmaceutical Co., Ltd.
18.30. WOLW Pharma Limited
List of Figures
FIGURE 1. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL ALLERGY IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ALLERGIC ASTHMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ALLERGIC ASTHMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ALLERGIC ASTHMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ALLERGIC RHINITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ALLERGIC RHINITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ALLERGIC RHINITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ATOPIC DERMATITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL URTICARIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL URTICARIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL URTICARIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ANIMAL DANDER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ANIMAL DANDER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL ANIMAL DANDER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL CAT ALLERGENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL CAT ALLERGENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL CAT ALLERGENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL DOG ALLERGENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL DOG ALLERGENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL DOG ALLERGENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL DUST MITES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL DUST MITES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL DUST MITES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL FOOD ALLERGENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL FOOD ALLERGENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL FOOD ALLERGENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL EGG ALLERGENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL EGG ALLERGENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL EGG ALLERGENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL MILK ALLERGENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL MILK ALLERGENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL MILK ALLERGENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL PEANUT ALLERGENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PEANUT ALLERGENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL PEANUT ALLERGENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL TREE NUT ALLERGENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL TREE NUT ALLERGENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL TREE NUT ALLERGENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL POLLEN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL POLLEN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL POLLEN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL DERMAL PATCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL DERMAL PATCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL DERMAL PATCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL DROPS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL DROPS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL DROPS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL INJECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL INJECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL INJECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ADJUVANTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ADJUVANTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ADJUVANTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL NANOTECHNOLOGY-BASED PLATFORMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL NANOTECHNOLOGY-BASED PLATFORMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL NANOTECHNOLOGY-BASED PLATFORMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL RECOMBINANT ALLERGENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL RECOMBINANT ALLERGENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL RECOMBINANT ALLERGENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL EPICUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL EPICUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL EPICUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ORAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ORAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ORAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL SUBCUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL SUBCUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL SUBCUTANEOUS IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SUBLINGUAL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SUBLINGUAL IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL SUBLINGUAL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL RESEARCH & ACADEMIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL RESEARCH & ACADEMIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL RESEARCH & ACADEMIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 117. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 125. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 126. NORTH AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 134. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 135. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 136. LATIN AMERICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 137. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 139. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 140. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 141. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 142. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 143. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 144. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 145. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 146. EUROPE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 155. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 156. MIDDLE EAST ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 157. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 158. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 159. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 160. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 161. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 162. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 163. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 164. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 165. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 166. AFRICA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 168. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 170. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 171. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 172. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 173. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 174. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 175. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 176. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 177. ASEAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 178. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 179. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 180. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 181. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 182. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 183. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 184. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 185. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 186. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 187. GCC ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 198. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 199. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 200. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 201. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 202. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 203. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 204. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 205. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 206. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 207. BRICS ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 208. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 209. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 210. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 211. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 212. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 213. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 214. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 215. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 216. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 217. G7 ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 218. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 219. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 220. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 221. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 222. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 223. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 224. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 225. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 226. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 227. NATO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 228. GLOBAL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 229. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 230. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 231. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 232. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 233. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 236. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 237. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 239. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 240. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 241. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 242. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 243. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 244. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 245. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 246. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 247. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 248. CANADA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 249. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 250. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 251. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 252. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 253. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 254. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 255. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 256. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 257. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 258. MEXICO ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 259. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 260. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 261. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 262. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 263. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 264. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 265. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 266. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 267. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 268. BRAZIL ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 269. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 270. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 271. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 272. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 273. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 274. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 275. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 276. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 277. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 278. UNITED KINGDOM ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 279. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 280. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 281. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 282. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 283. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 284. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 285. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 286. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 287. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 288. GERMANY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 289. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 290. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 291. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 292. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 293. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 294. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 295. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 296. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 297. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 298. FRANCE ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 299. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 300. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 301. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 302. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 303. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 304. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 305. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 306. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 307. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 308. RUSSIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 309. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 310. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 311. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 312. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 313. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 314. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 315. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 316. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 317. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 318. ITALY ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 319. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 320. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 321. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 322. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 323. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 324. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 325. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 326. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 327. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 328. SPAIN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 329. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 330. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 331. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 332. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 333. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 334. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 335. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 336. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 337. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 338. CHINA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 339. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 340. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 341. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 342. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 343. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 344. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY IMMUNOTHERAPY DELIVERY FORM, 2017-2032 (USD MILLION)
TABLE 345. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 346. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 347. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 348. INDIA ALLERGY IMMUNOTHERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 349. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 350. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGY TYPE, 2017-2032 (USD MILLION)
TABLE 351. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ALLERGEN TYPE, 2017-2032 (USD MILLION)
TABLE 352. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY ANIMAL DANDER, 2017-2032 (USD MILLION)
TABLE 353. JAPAN ALLERGY IMMUNOTHERAPY MARKET SIZE, BY FOOD ALLERGENS, 2017-2032 (USD MILLION)
TABLE 354.

Companies Mentioned

  • Adamis Pharmaceuticals Corporation
  • Aimmune Therapeutics Inc.
  • ALK‑Abelló A/S
  • Allergopharma GmbH & Co. KG
  • Allergy Therapeutics plc
  • Allovate LLC
  • Anergis SA
  • ASIT Biotech SA
  • Biomay AG
  • Camallergy Ltd.
  • Circassia Pharmaceuticals Inc.
  • DBV Technologies SA
  • Desentum Oy
  • HAL Allergy B.V.
  • HollisterStier Allergy Inc.
  • Inimmune Corporation
  • Inmunotek S.L.
  • Intrommune Therapeutics, Inc.
  • Jubilant HollisterStier LLC
  • LETI Pharma S.L.
  • Leti‑allergoid
  • Merck KGaA
  • Mylan N.V.
  • Novartis AG
  • Prota Therapeutics Pty Ltd
  • Siolta Therapeutics, Inc.
  • Stallergenes Greer International AG
  • Thermo Fisher Scientific Inc.
  • Torii Pharmaceutical Co., Ltd.
  • WOLW Pharma Limited

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.24 Billion
Forecasted Market Value ( USD ) by 2032 $ 4.07 Billion
Compound Annual Growth Rate10.3%
Regions CoveredGlobal
No. of Companies Mentioned30

Related Topics

Related Reports

Allergy Vaccine Market - Global Forecast 2026-2032 - Product Image

Allergy Vaccine Market - Global Forecast 2026-2032

  • Report
  • 181 Pages
  • Global
From
Allergy Treatment Market - Global Forecast 2026-2032 - Product Image

Allergy Treatment Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Allergy Immunotherapies Market Size, Share, Trends and Forecast by Treatment Type, Allergy Type, Distribution Channel, and Region, 2026-2034 - Product Image

Allergy Immunotherapies Market Size, Share, Trends and Forecast by Treatment Type, Allergy Type, Distribution Channel, and Region, 2026-2034

  • Report
  • 145 Pages
  • Global
From
Allergy Immunotherapy - Global Strategic Business Report - Product Image

Allergy Immunotherapy - Global Strategic Business Report

  • Report
  • 266 Pages
  • Global
From
Allergy Immunotherapy Market Report 2026 - Product Image

Allergy Immunotherapy Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Allergy Immunotherapy Market

Allergy Immunotherapy is a form of treatment for allergies that involves administering small doses of allergens to the patient over a period of time. This helps the patient build up a tolerance to the allergens, reducing the severity of their allergic reactions. Allergy Immunotherapy is often used in conjunction with other forms of allergy treatment, such as antihistamines and decongestants. Allergy Immunotherapy is a growing market, with a variety of products available to treat different types of allergies. These products range from sublingual drops and tablets to injections and nasal sprays. Many of these products are available over the counter, while others require a prescription from a doctor. The Allergy Immunotherapy market is highly competitive, with many companies offering products to treat different types of allergies. Some of the major players in the market include ALK-Abello, Stallergenes Greer, Merck, Allergy Therapeutics, and Circassia. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.